Not Yet RecruitingNot Applicable

COLON ERDERLY LOW DOSE

Italy51 participantsStarted 2026-02-01

Plain-language summary

In this retrospective observational study, the case series of patients undergoing first-line treatment for metastatic colorectal adenocarcinoma with doublet fixed-dose and reduced-dose chemotherapy in combination with full-dose monoclonal antibody in patients aged 70 years or older is collected.

Who can participate

Age range70 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with metastatic colorectal adenocarcinoma not treated with any therapy in the metastatic phase. Previous (neo)-adjuvant treatment with fluoroderivatives with or without Oxaliplatin is permitted.
✓. Age ≥ 70 years
✓. G8 score ≥ 12
✓. Patients with colorectal adenocarcinoma MSS
✓. Patients with BRAF WT colorectal adenocarcinoma
✓. Ability to understand and sign the informed consent form.

Exclusion criteria

✕. Patients with MSI tumours
✕. Patients with BRAF V600E mutated tumours
✕. Patients not eligible for doublet chemotherapy by clinical decision

What they're measuring

Neutropenia incidence

Timeframe: 24 months

Diarrehea incidence

Timeframe: 24 months

Trial details

NCT IDNCT06840977

SponsorMatteo Clavarezza

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-06-30

Contact for this trial

Matteo Clavarezza

010.5634580 matteo.clavarezza@galliera.it

View on ClinicalTrials.gov More Colon Adenocarcinoma trials